Class IIOngoingD-0767-2026
Drug recall · August 26, 2026
Libtayo recall
Why: Lack of Assurance of Sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01
- Lots / codes
Lot: 8494000002, Exp 7/31/28
- Quantity
- 21,353 vials
- Company
- Regeneron Pharmaceuticals Inc, Tarrytown, NY
- Distribution
- USA Nationwide
- Initiated
- July 28, 2026 · Voluntary: Firm initiated
- Classified
- August 14, 2026
- Reported
- August 26, 2026
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.